Key result
Aminoguanidine alleviates reperfusion congestion, whereas NAME totally inhibits NO and impairs myocardial perfusion.
Why the study?
The differential effects of selective and non-selective nitric oxide synthase inhibitors on blood flow perfusion in ischemia-reperfused myocardium were unclear.
Do selective (aminoguanidine) or non-selective (NAME) NOS inhibitors improve blood perfusion in ischemia-reperfused myocardium in dogs?
Population
Male mongrel dogs subjected to ischemia-reperfusion
Comparison
Nù-nitro-L-arginine methyl ester vs aminoguanidine vs ischemia-reperfusion control vs sham operation
Design
Randomized controlled preclinical study
Follow-up
90 minutes of reperfusion
Authors
Loading...
Non-selective NOS inhibition may worsen myocardial hypoperfusion after reperfusion; leaves open whether selective iNOS blockade merits human trials.
RCT
randomly assigned
Do selective (aminoguanidine) or non-selective (NAME) NOS inhibitors improve blood perfusion in ischemia-reperfused myocardium in dogs?
Selective iNOS inhibition with aminoguanidine may alleviate congestion and improve perfusion in ischemia-reperfused myocardium, whereas non-selective NOS inhibition with NAME attenuates perfusion.
Luo et al. (2013) conducted an RCT in ischemia-reperfused myocardium. Nù-nitro-L-arginine methyl ester (NAME) and aminoguanidine (AMD) vs. ischemia-reperfusion only (control) and sham operation was evaluated on Blood flow perfusion (PVI and PVI ratio) and NO concentration. Aminoguanidine significantly relieved the increase in NO production and alleviated congestion of reperfused myocardium, whereas NAME totally inhibited NO production and attenuated blood flow perfusion.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: